Welcome to 2nd B & T Cell-Mediated Autoimmune Disease Drug Development Summit
The year's summit will focus on optimizing therapeutic targeting of the bidirectional interactions between B and T cells, B cell functions (autoantibody production, antigen presentation, T cell help and cytokine production) and autoreactive T cells contribution to autoimmune pathogenesis and disease progression.
Hear clinical case studies of novel and targeted approaches, advancements in organ-specific drug delivery and engineered cellular immunotherapies, plus the drug development rationale for various combinatorial and biomarker-led clinical trial investigations, targeted approaches, engineering cell immunotherapy, antigen-specific therapies, organ specificity, cytokines, combination strategy and the future for biomarkers.
Key Discussions you Can’t Afford to Miss:
Delve into the exciting world of cell engineering and novel targets for rare autoimmune diseases and what they mean for the field with Abcuro, Polyneuron, Apitope, NYSCF, UTHSC & Cabaletta Bio
Discover the novel and promising candidates targeting B cell development factors and related cytokines with Eli Lilly & Co, UCL, Kyverna, Immunic AG, Nurix & GSK
Uncover the pathologies and targets for the B & T cell co-stimulatory pathways and novel mechanisms in disrupting collaboration with Artax Bio, Cytocom, Horizon, AltruBio & Novartis
Explore targets, considerations and strategy for targeting autoantibody producing plasma cells, organ specific and systemic diseases with UCB, Provention Bio, IM Therapeutics & Biogen
Optimize application and patient outlook through combination strategies, early detection and emerging biomarkers and look to next steps in your drug development with Oklahoma Medical Research Foundation, Bristol-Myers Squibb & Eli Lilly & Co